Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Kezar Life Sciences, Inc.

< Previous 1 2 Next >
Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN’s Kidney Week 2022 Annual Meeting
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology’s Kidney Week 2022 Annual Meeting
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences to Present at the William Blair Biotech Focus Conference
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
Kezar Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Tickers KZR
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS